We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
No fiscal-year history available for this company yet.
No P/E, the company is not profitable on a trailing basis.
Vilin Bio Med Ltd. is a domestic pharmaceutical company primarily engaged in the manufacturing and trading of pharmaceutical products, with a focus on generic formulations across various therapeutic segments. The company produces pharmaceutical formulations such as oral liquids, dry syrups, sachets, external preparations, beta and non-beta lactam tablets and capsules, and nutritional food supplements. These products address therapeutic areas including anti-infectives, analgesics, cardiovascular, musculoskeletal, antibiotic, central nervous system, alimentary system, genito-urinary tract, respiratory system, anti-allergic, and anti-diabetic conditions. Vilin Bio Med also engages in contract manufacturing and the distribution of its own branded generics, supplying products in bulk to pharmaceutical manufacturers, marketers, and traders. Beyond pharmaceuticals, the company offers a range of cosmetics, including products for baby care, skin care, oral care, and hair care, such as serums, oils, lotions, creams, cleansers, moisturizers, and masks. The primary target market for Vilin Bio Med is the domestic Indian market, which generates over 90% of its revenue, though it also has international operations and a U.S. subsidiary for marketing and distribution in the United States, alongside a presence in GCC, Africa, EU, and Asia.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save VILINBIO.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
